Literature DB >> 12239617

Value of expression of p21WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy.

Nobuhito Sogawa1, Nobuhiro Takiguchi, Keiji Koda, Kenji Oda, Daisuke Satomi, Kazuki Kato, Hiroshi Ishikura, Masaru Miyazaki.   

Abstract

Recent molecular biological studies suggested certain molecular markers might be useful as prognostic factors in patients with colorectal cancer. The purpose of this study was to investigate whether cyclin dependent inhibitor kinase p21WAF1/CIP1 (p21), p53 expression, and/or the presence of apoptosis had prognostic value in predicting survival in patients with advanced middle and lower rectal cancer who were treated with preoperative radio-chemotherapy. We examined the immunohistochemical expression of p21 and p53, and determined the degree of apoptosis in resected middle and lower rectal cancers from patients who received preoperative radio-chemotherapy (irradiation group, n=40) and from those who did not receive treatment (control group, n=35). The preoperative total radiotherapy dose was 42.6 Gy and the chemotherapy tegafur suppository dose was 750 mg/day. Clinicopathological features, and tumor expression of p53 and p21 and degree of apoptosis were analyzed by means of multivariate analysis. In the irradiation group, tumors were positive for p53, p21 and apoptosis in 34 of 40 (85.0%), 23 of 40 (57.5%) and 25 of 40 (62.5%) cases, respectively. The expression of p21 and the apoptotic index were significantly higher in the irradiated group compared to controls (2.0 versus 1.2%, p=0.05; 8 versus 3%, p=0.03, respectively). There was a significant correlation between p21 immunoreactivity and the degree of muscularis propria invasion (p=0.004), as well as between p21 immunoreactivity and survival rate (p=0.03). Multivariate analysis revealed that p21 expression (RR, 0.09; 95% CI, 0.01-0.78; p=0.03) and lymph node metastasis (RR, 3.63; 95% CI, 1.06-12.37; p=0.04) were significant prognostic factors for patient survival. These data suggested that p21 expression has prognostic value in predicting patient survival in advanced middle and lower rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239617

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Akemi Kamijo; Takeshi Akiba; Shuichi Kawada
Journal:  Int J Clin Oncol       Date:  2015-04-02       Impact factor: 3.402

2.  p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease.

Authors:  Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem
Journal:  Am J Surg       Date:  2014-04-13       Impact factor: 2.565

3.  Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation.

Authors:  Atilla Kurt; Fatih Yanar; Oktar Asoglu; Emre Balik; Vakur Olgac; Hasan Karanlik; Sevda Tanrikulu Kucuk; Evin Ademoglu; Gulcin Yegen; Dursun Bugra
Journal:  BMC Clin Pathol       Date:  2012-12-31

4.  Use of RNA-Seq and a Transgenic Mouse Model to Identify Genes Which May Contribute to Mutant p53-Driven Prostate Cancer Initiation.

Authors:  Ruth Vinall; Qian Chen; George Talbott; Rajendra Ramsamooj; An Dang; Clifford G Tepper; Alexander Borowsky
Journal:  Biology (Basel)       Date:  2022-01-29

5.  APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.

Authors:  Russell D Petty; Leslie M Samuel; Graeme I Murray; Graham MacDonald; Terrence O'Kelly; Malcolm Loudon; Norman Binnie; Emad Aly; Aileen McKinlay; Weiguang Wang; Fiona Gilbert; Scot Semple; Elaina S R Collie-Duguid
Journal:  BMC Cancer       Date:  2009-12-11       Impact factor: 4.430

6.  P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.

Authors:  Sung Hoon Sim; Mi-Hyun Kang; Yu Jung Kim; Keun-Wook Lee; Duck-Woo Kim; Sung-Bum Kang; Keun-Yong Eom; Jae-Sung Kim; Hye Seung Lee; Jee Hyun Kim
Journal:  BMC Cancer       Date:  2014-04-04       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.